Ch-10 Biotechnology and its application
Ch-10 Biotechnology and its application
APPLICATIONS IN AGRICULTURE
Bt cotton
- Some strains of Bacillus thuringiensis have proteins that kill insects like coleopterans (beetles),
lepidopterans (tobacco budworm, armyworm) & dipterans (flies, mosquitoes).
- B. thuringiensis forms an insecticidal protein (Bt toxin) crystal during a phase of their growth. It does not
kill the Bacillus as it exists as inactive protoxins.
- When an insect ingests the toxin, it becomes active due to the alkaline pH of the gut which solubilises the
crystals. The toxin binds to the surface of mid-gut epithelial cells creating pores. It causes cell swelling,
lysis and death of the insect.
- Bt toxin genes were isolated from B. thuringiensis and incorporated into crop plants such as cotton.
- Most Bt toxins are insect-group specific. They are coded by cry genes. E.g. proteins encoded by cryIAc &
cryIIAb genes control cotton bollworms. The protein of the cryIAb gene controls corn borer.
Nematode resistance in tobacco plants:
- A nematode Meloidogyne incognita infects the roots of tobacco plants causing a reduction in yield.
- It can be prevented by RNA interference (RNAi) strategy.
- RNAi is a method of cellular defence in all eukaryotic organisms. It prevents the translation of a specific
mRNA (silencing) due to a complementary dsRNA molecule.
- The source of this complementary RNA is from an infection by RNA viruses or mobile genetic elements
(transposons) that replicate via an RNA intermediate.
- Isolate Nematode-specific genes (DNA). It is introduced into the host plant using Agrobacterium vectors.
It produces both sense & anti-sense RNA in host cells. These RNAs are complementary. So, they form
double-stranded (ds) RNA. It initiates RNAi and silences the specific mRNA of the nematode. Thus, the
parasite cannot survive in a transgenic host expressing specific interfering RNA.
APPLICATIONS IN MEDICINE
- Recombinant DNA technology helps for the mass production of safe and more effective therapeutic drugs.
- Products from non-human sources cause unwanted immunological responses. However recombinant
therapeutics do not have such problems.
- At present, about 30 recombinant therapeutics have been approved. Of these, 12 are being marketed in
India.
-
1. Genetically Engineered Insulin
- The pro-hormone contains an extra stretch called C peptide. This is removed during maturation into
insulin.
- In 1983, Eli Lilly (an American company) prepared two DNA sequences corresponding to A
& B chains of human insulin and introduced them in plasmids of E. coli to produce insulin chains. Chains
A & B were combined by creating disulfide bonds to form human insulin (Humulin).
2. Gene Therapy
- Gene therapy for ADA deficiency: Collect lymphocytes from the patient’s blood and grow in a culture
→ Introduce a functional ADA cDNA into lymphocytes (using a retroviral vector) → They are returned to
the patient.
This should be periodically repeated as lymphocytes are not immortal.
- If the ADA gene from marrow cells is introduced into cells at early embryonic stages, it could be a
permanent cure.
3. Molecular Diagnosis
- Conventional methods (serum & urine analysis) are not suitable for early diagnosis of diseases.
- It is possible by techniques such as Recombinant DNA technology, PCR & ELISA
- The presence of a pathogen is normally suspected only based on symptoms. By this time, the concentration
of pathogens is already very high in the body.
- However, very low concentrations of bacteria or viruses can be detected by amplification of their nucleic
acid by PCR.
- Uses of PCR:
• To detect HIV in suspected patients.
• To detect gene mutations in suspected cancer patients.
• To identify many other genetic disorders.
- A single-stranded DNA or RNA, tagged with a radioactive molecule (probe) is hybridised to its
complementary DNA in a clone of cells. It is detected by autoradiography. The clone having a mutated
gene will not appear on photographic film, because the probe will not have complementarity with the
mutated gene.
- These are the animals whose genome has been altered by the introduction of a foreign gene by manipulation.
- E.g. Transgenic rats, rabbits, pigs, sheep, cows and fish.
- Over 95% of the transgenic animals are mice.
• To study the regulation of genes and their action on normal physiology & development: E.g. Study of
insulin-like growth factor. Genes (from other species) that alter the formation of this factor are introduced
and the biological effects are studied. This gives information about the biological role of the factor.
• To study the contribution of genes in the development of a disease and thereby new treatments: E.g.
transgenic models for human diseases such as cancer, cystic fibrosis, rheumatoid arthritis & Alzheimer’s.
• Biological products: Some medicines contain expensive biological products. Transgenic animals can be
used to produce biological products by introducing genes which codes for a particular product.
They are used to treat diseases such as emphysema, phenylketonuria (PKU), cystic fibrosis etc. E.g. human
protein (α-1-antitrypsin) used to treat emphysema.
In 1997, Rosie (the first transgenic cow) produced human protein-enriched milk (2.4 gm per litre). It
contains human α-lactalbumin. It is a nutritionally more balanced product for human babies than natural
cow milk.
• Vaccine safety testing: Transgenic mice are used to test the safety of the polio vaccine. If it is reliable, they
can replace the use of monkeys to test the safety of vaccines.
• Chemical safety testing (toxicity testing): Some transgenic animals carry genes which make them more
sensitive to toxic substances than non-transgenic animals. They are exposed to the toxic substances and the
effects studied. It gives immediate results.
ETHICAL ISSUES
• Bio-piracy: It is the use of bio-resources by multinational companies and other organisations without proper
authorization from the countries and people concerned. Certain companies have patents for products and
technologies that make use of the genetic materials, plants etc. that have been identified, developed and
used by farmers and indigenous people of a country. E.g. Basmati rice, herbal medicines (turmeric, neem
etc.).
• Basmati rice has a unique aroma & flavour. India has 27 varieties of Basmati. In 1997, an American
company got patent rights on Basmati rice through the US Patent and Trademark Office. This allowed
the company to sell a ‘new’ variety of Basmati. This was actually derived from Indian farmer’s varieties.
Indian Basmati was crossed with semi-dwarf varieties and claimed as a novelty. Other people selling
Basmati rice could be restricted by patent.
Generally, industrialised nations are poor in biodiversity and traditional knowledge. The developing and
underdeveloped world has rich biodiversity and traditional knowledge related to bio-resources.
It has to develop laws to prevent unauthorised exploitation of bio-resources and traditional knowledge.
Indian Parliament has cleared the second amendment of the Indian Patents Bill that has considered patent
terms emergency provisions and research and development initiatives.